A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes multiple clinical-stage investigational therapies, including: (1) two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus (HDV) entry inhibitor; and (3) a highly potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Our pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is currently undergoing studies to enable a regulatory filing, and we have additional research programs against multiple antiviral targets.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 37M | 29M | - | - | - | 79M |
| Net Income | -39M | -40M | -61M | -93M | -130M | -62M |
| EPS | $-4.60 | $-6.69 | $-160.56 | $-276.96 | $-36.00 | $-21.00 |
| Free Cash Flow | -56M | -51M | 22M | -85M | -96M | -63M |
| ROIC | -14.3% | -107.9% | -149.0% | -112.6% | -76.9% | -25.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.09 | 0.06 | 0.04 | 0.04 | 0.04 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -43M | -45M | -65M | -94M | -133M | -65M |
| Operating Margin | -116.8% | -159.3% | - | - | - | -81.9% |
| ROE | -21.1% | -107.9% | -149.0% | -112.6% | -76.9% | -25.8% |
| Shares Outstanding | 16M | 6M | 0M | 0M | 4M | 3M |
ASSEMBLY BIOSCIENCES, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +30.9%.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a 5-year average return on invested capital (ROIC) of -94.4%. This is below average and may indicate limited pricing power.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a market capitalization of $466M. It is classified as a small-cap stock.
ASSEMBLY BIOSCIENCES, INC. (ASMB) does not currently pay a regular dividend.
ASSEMBLY BIOSCIENCES, INC. (ASMB) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ASSEMBLY BIOSCIENCES, INC. (ASMB) reported annual revenue of $29 million in its most recent fiscal year, based on SEC EDGAR filings.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a net profit margin of -140.9%. The company is currently unprofitable.
ASSEMBLY BIOSCIENCES, INC. (ASMB) generated $-51 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a debt-to-equity ratio of 0.09. This indicates a conservatively financed balance sheet.
ASSEMBLY BIOSCIENCES, INC. (ASMB) reported earnings per share (EPS) of $-6.69 in its most recent fiscal year.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a return on equity (ROE) of -107.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 12 years of financial data for ASSEMBLY BIOSCIENCES, INC. (ASMB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a book value per share of $5.55, based on its most recent annual SEC filing.